RT Journal Article SR Electronic T1 Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 649 OP 654 DO 10.2967/jnumed.119.232827 VO 61 IS 5 A1 Aiping Chen A1 Fatima-Zohra Mokrane A1 Lawrence H. Schwartz A1 Franck Morschhauser A1 Apasia Stamatoullas A1 Jean-Marc Schiano de Colella A1 Laetitia Vercellino A1 Olivier Casasnovas A1 Adrien Chauchet A1 Alain Delmer A1 Emmanuelle Nicolas-Virelizier A1 Hervé Ghesquières A1 Marie-Pierre Moles-Moreau A1 Anna Schmitt A1 Rémy Dulery A1 Krimo Bouabdallah A1 Cecile Borel A1 Mohamed Touati A1 Benedicte Deau-Fischer A1 Frédéric Peyrade A1 Romain-David Seban A1 Guillaume Manson A1 Philippe Armand A1 Roch Houot A1 Laurent Dercle YR 2020 UL http://jnm.snmjournals.org/content/61/5/649.abstract AB Monoclonal antibodies (mAbs) against programmed cell death 1 (PD-1), such as nivolumab and pembrolizumab, are associated with high response rates in patients with relapsed or refractory classic Hodgkin lymphoma (HL). To date, no prognostic factor for overall survival (OS) has been established with these agents in HL. We examined whether the first early response assessment evaluated using 18F-FDG PET/CT may be associated with OS in this setting. Methods: This retrospective study included 45 patients from 34 institutions. In a masked, centralized review, 3 independent radiologists classified PET/CT scans obtained at a median of 2.0 mo (interquartile range, 1.7–3.7 mo) after nivolumab initiation using existing criteria (i.e., 2014 Lugano classification and 2016 LYRIC). Patients were classified according to 4 possible response categories: complete metabolic response (CMR), partial metabolic response (PMR), no metabolic response (NMR), or progressive metabolic disease (PMD). Because the OS of patients with NMR and PMR was similar, they were grouped together. OS was estimated using the Kaplan–Meier method and compared between groups using log-rank testing. Results: Eleven patients (24%) died after a median follow-up of 21.2 mo. The classification was identical between Lugano and LYRIC because all 16 progression events classified as indeterminate response per LYRIC were confirmed on subsequent evaluations. Both Lugano and LYRIC classified patients as CMR in 13 cases (29%), PMD in 16 (36%), NMR in 4 (9%), and PMR in 12 (27%). The 2-y OS probability was significantly different in patients with PMD (0.53; 95% confidence interval [95%CI], 0.32–0.87), NMR or PMR (0.80; 95%CI, 0.63–1.00), and CMR (1.00; 95%CI, 1.00–1.00) in the overall population (P = 0.02, 45 patients), as well as according to a landmark analysis at 3 mo (P = 0.05, 32 patients). Conclusion: In relapsed or refractory HL patients treated with anti-PD-1 mAbs, the first early PET/CT assessment using either Lugano or LYRIC predicted OS and allowed early risk stratification, suggesting that PET/CT might be used to develop risk-adapted strategies.